Switch to:
Also traded in: Germany, Mexico, UK, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.03
SHPGF's Cash to Debt is ranked lower than
98% of the 947 Companies
in the Global Biotechnology industry.

( Industry Median: 45.69 vs. SHPGF: 0.03 )
Ranked among companies with meaningful Cash to Debt only.
SHPGF' s Cash to Debt Range Over the Past 10 Years
Min: 0.01  Med: 1.32 Max: No Debt
Current: 0.03
Equity to Asset 0.43
SHPGF's Equity to Asset is ranked lower than
76% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. SHPGF: 0.43 )
Ranked among companies with meaningful Equity to Asset only.
SHPGF' s Equity to Asset Range Over the Past 10 Years
Min: 0.25  Med: 0.58 Max: 0.85
Current: 0.43
0.25
0.85
Interest Coverage 1.57
SHPGF's Interest Coverage is ranked lower than
97% of the 460 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. SHPGF: 1.57 )
Ranked among companies with meaningful Interest Coverage only.
SHPGF' s Interest Coverage Range Over the Past 10 Years
Min: 1.57  Med: 27.36 Max: 55.13
Current: 1.57
1.57
55.13
F-Score: 5
Z-Score: 1.10
M-Score: -1.62
WACC vs ROIC
10.10%
3.27%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 5.67
SHPGF's Operating margin (%) is ranked higher than
75% of the 734 Companies
in the Global Biotechnology industry.

( Industry Median: -88.05 vs. SHPGF: 5.67 )
Ranked among companies with meaningful Operating margin (%) only.
SHPGF' s Operating margin (%) Range Over the Past 10 Years
Min: -56.61  Med: 22.5 Max: 35.13
Current: 5.67
-56.61
35.13
Net-margin (%) 1.09
SHPGF's Net-margin (%) is ranked higher than
71% of the 734 Companies
in the Global Biotechnology industry.

( Industry Median: -76.71 vs. SHPGF: 1.09 )
Ranked among companies with meaningful Net-margin (%) only.
SHPGF' s Net-margin (%) Range Over the Past 10 Years
Min: -59.59  Med: 16.4 Max: 56.55
Current: 1.09
-59.59
56.55
ROE (%) 0.57
SHPGF's ROE (%) is ranked higher than
75% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: -33.76 vs. SHPGF: 0.57 )
Ranked among companies with meaningful ROE (%) only.
SHPGF' s ROE (%) Range Over the Past 10 Years
Min: -90.17  Med: 17.81 Max: 49.41
Current: 0.57
-90.17
49.41
ROA (%) 0.26
SHPGF's ROA (%) is ranked higher than
77% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: -29.98 vs. SHPGF: 0.26 )
Ranked among companies with meaningful ROA (%) only.
SHPGF' s ROA (%) Range Over the Past 10 Years
Min: -37.5  Med: 9.76 Max: 31.57
Current: 0.26
-37.5
31.57
ROC (Joel Greenblatt) (%) 10.32
SHPGF's ROC (Joel Greenblatt) (%) is ranked higher than
81% of the 916 Companies
in the Global Biotechnology industry.

( Industry Median: -407.53 vs. SHPGF: 10.32 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
SHPGF' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -396.76  Med: 110.51 Max: 345.74
Current: 10.32
-396.76
345.74
Revenue Growth (3Y)(%) 15.20
SHPGF's Revenue Growth (3Y)(%) is ranked higher than
67% of the 472 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. SHPGF: 15.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
SHPGF' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -0.8  Med: 11.8 Max: 26.7
Current: 15.2
-0.8
26.7
EBITDA Growth (3Y)(%) 18.10
SHPGF's EBITDA Growth (3Y)(%) is ranked higher than
69% of the 517 Companies
in the Global Biotechnology industry.

( Industry Median: 1.70 vs. SHPGF: 18.10 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
SHPGF' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -1.9  Med: 20.75 Max: 34.1
Current: 18.1
-1.9
34.1
EPS Growth (3Y)(%) 21.50
SHPGF's EPS Growth (3Y)(%) is ranked higher than
77% of the 502 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. SHPGF: 21.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
SHPGF' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -7.3  Med: 30.55 Max: 68.8
Current: 21.5
-7.3
68.8
GuruFocus has detected 3 Warning Signs with Shire PLC $SHPGF.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» SHPGF's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with SHPGF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:BIIB, NAS:REGN, OTCPK:CSLLY, NAS:ALXN, OTCPK:ALIOY, NAS:INCY, NAS:VRTX, NAS:BMRN, OTCPK:UCBJY, NAS:CELG, OTCPK:GMXAY, OTCPK:GIFOF, OTCPK:NVZMF, NYSE:NVO, NAS:ALKS, NAS:TSRO, NAS:SGEN, NAS:GILD, NAS:JAZZ, NAS:UTHR » details
Traded in other countries:S7E.Germany, SHPG N.Mexico, SHP.UK, SHPG.USA,
Shire PLC is a specialty biopharmaceutical company that focuses on developing and marketing specialty medicines that address unmet patient needs.

Shire PLC is a biotech company incorporated and registered in Jersey on January 28, 2008. The Company is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of medicines to meet unmet patient needs. Its Products include FIRAZYR, LDX, NATPAR, SHP609, GATTEX, INTUNIV, TYVENSE, VENVANSE, OBIZUR, HEMOFIL, FOZNOL among others. The Company develops products, many of which are available in more than 100 countries, across core therapeutic areas including Hematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; and a franchise in Oncology.

Ratios

vs
industry
vs
history
P/E(ttm) 145.69
SHPGF's P/E(ttm) is ranked lower than
89% of the 246 Companies
in the Global Biotechnology industry.

( Industry Median: 28.42 vs. SHPGF: 145.69 )
Ranked among companies with meaningful P/E(ttm) only.
SHPGF' s P/E(ttm) Range Over the Past 10 Years
Min: 12.4  Med: 26.15 Max: 162.3
Current: 145.69
12.4
162.3
Forward P/E 10.66
SHPGF's Forward P/E is ranked higher than
85% of the 61 Companies
in the Global Biotechnology industry.

( Industry Median: 17.86 vs. SHPGF: 10.66 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 80.38
SHPGF's PE(NRI) is ranked lower than
80% of the 244 Companies
in the Global Biotechnology industry.

( Industry Median: 28.58 vs. SHPGF: 80.38 )
Ranked among companies with meaningful PE(NRI) only.
SHPGF' s PE(NRI) Range Over the Past 10 Years
Min: 12.87  Med: 23.14 Max: 106.93
Current: 80.38
12.87
106.93
Price/Owner Earnings (ttm) 43.45
SHPGF's Price/Owner Earnings (ttm) is ranked lower than
62% of the 142 Companies
in the Global Biotechnology industry.

( Industry Median: 28.43 vs. SHPGF: 43.45 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
SHPGF' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 11.33  Med: 24.13 Max: 72.9
Current: 43.45
11.33
72.9
P/B 1.85
SHPGF's P/B is ranked higher than
74% of the 845 Companies
in the Global Biotechnology industry.

( Industry Median: 3.62 vs. SHPGF: 1.85 )
Ranked among companies with meaningful P/B only.
SHPGF' s P/B Range Over the Past 10 Years
Min: 1.7  Med: 5.49 Max: 14.19
Current: 1.85
1.7
14.19
P/S 4.97
SHPGF's P/S is ranked higher than
71% of the 682 Companies
in the Global Biotechnology industry.

( Industry Median: 10.89 vs. SHPGF: 4.97 )
Ranked among companies with meaningful P/S only.
SHPGF' s P/S Range Over the Past 10 Years
Min: 2.25  Med: 4.68 Max: 9.24
Current: 4.97
2.25
9.24
POCF 19.65
SHPGF's POCF is ranked higher than
52% of the 179 Companies
in the Global Biotechnology industry.

( Industry Median: 21.07 vs. SHPGF: 19.65 )
Ranked among companies with meaningful POCF only.
SHPGF' s POCF Range Over the Past 10 Years
Min: 7.66  Med: 17.07 Max: 27
Current: 19.65
7.66
27
EV-to-EBIT 158.36
SHPGF's EV-to-EBIT is ranked lower than
96% of the 241 Companies
in the Global Biotechnology industry.

( Industry Median: 20.60 vs. SHPGF: 158.36 )
Ranked among companies with meaningful EV-to-EBIT only.
SHPGF' s EV-to-EBIT Range Over the Past 10 Years
Min: -16.1  Med: 16.8 Max: 173.7
Current: 158.36
-16.1
173.7
EV-to-EBITDA 30.30
SHPGF's EV-to-EBITDA is ranked lower than
69% of the 264 Companies
in the Global Biotechnology industry.

( Industry Median: 17.09 vs. SHPGF: 30.30 )
Ranked among companies with meaningful EV-to-EBITDA only.
SHPGF' s EV-to-EBITDA Range Over the Past 10 Years
Min: -19.6  Med: 13.5 Max: 33.2
Current: 30.3
-19.6
33.2
PEG 3.92
SHPGF's PEG is ranked lower than
68% of the 98 Companies
in the Global Biotechnology industry.

( Industry Median: 2.14 vs. SHPGF: 3.92 )
Ranked among companies with meaningful PEG only.
SHPGF' s PEG Range Over the Past 10 Years
Min: 0.47  Med: 1.09 Max: 4.43
Current: 3.92
0.47
4.43
Shiller P/E 58.30
SHPGF's Shiller P/E is ranked lower than
54% of the 56 Companies
in the Global Biotechnology industry.

( Industry Median: 46.84 vs. SHPGF: 58.30 )
Ranked among companies with meaningful Shiller P/E only.
SHPGF' s Shiller P/E Range Over the Past 10 Years
Min: 42.92  Med: 102.43 Max: 469
Current: 58.3
42.92
469
Current Ratio 1.25
SHPGF's Current Ratio is ranked lower than
84% of the 947 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. SHPGF: 1.25 )
Ranked among companies with meaningful Current Ratio only.
SHPGF' s Current Ratio Range Over the Past 10 Years
Min: 0.52  Med: 1.72 Max: 7.43
Current: 1.25
0.52
7.43
Quick Ratio 0.57
SHPGF's Quick Ratio is ranked lower than
91% of the 946 Companies
in the Global Biotechnology industry.

( Industry Median: 3.85 vs. SHPGF: 0.57 )
Ranked among companies with meaningful Quick Ratio only.
SHPGF' s Quick Ratio Range Over the Past 10 Years
Min: 0.4  Med: 1.51 Max: 7.07
Current: 0.57
0.4
7.07
Days Inventory 299.72
SHPGF's Days Inventory is ranked lower than
84% of the 437 Companies
in the Global Biotechnology industry.

( Industry Median: 127.64 vs. SHPGF: 299.72 )
Ranked among companies with meaningful Days Inventory only.
SHPGF' s Days Inventory Range Over the Past 10 Years
Min: 126.5  Med: 190.45 Max: 299.72
Current: 299.72
126.5
299.72
Days Sales Outstanding 109.45
SHPGF's Days Sales Outstanding is ranked lower than
74% of the 591 Companies
in the Global Biotechnology industry.

( Industry Median: 62.07 vs. SHPGF: 109.45 )
Ranked among companies with meaningful Days Sales Outstanding only.
SHPGF' s Days Sales Outstanding Range Over the Past 10 Years
Min: 47.71  Med: 67.39 Max: 109.45
Current: 109.45
47.71
109.45

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.46
SHPGF's Dividend Yield is ranked lower than
88% of the 232 Companies
in the Global Biotechnology industry.

( Industry Median: 1.24 vs. SHPGF: 0.46 )
Ranked among companies with meaningful Dividend Yield only.
SHPGF' s Dividend Yield Range Over the Past 10 Years
Min: 0.23  Med: 0.41 Max: 0.7
Current: 0.46
0.23
0.7
Dividend Payout 0.41
SHPGF's Dividend Payout is ranked lower than
57% of the 127 Companies
in the Global Biotechnology industry.

( Industry Median: 0.32 vs. SHPGF: 0.41 )
Ranked among companies with meaningful Dividend Payout only.
SHPGF' s Dividend Payout Range Over the Past 10 Years
Min: 0.04  Med: 0.1 Max: 0.41
Current: 0.41
0.04
0.41
Dividend Growth (3y) 16.70
SHPGF's Dividend Growth (3y) is ranked higher than
72% of the 88 Companies
in the Global Biotechnology industry.

( Industry Median: 7.70 vs. SHPGF: 16.70 )
Ranked among companies with meaningful Dividend Growth (3y) only.
SHPGF' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 0  Med: 15.4 Max: 57.8
Current: 16.7
0
57.8
Forward Dividend Yield 0.46
SHPGF's Forward Dividend Yield is ranked lower than
89% of the 214 Companies
in the Global Biotechnology industry.

( Industry Median: 1.41 vs. SHPGF: 0.46 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 1.00
SHPGF's Yield on cost (5-Year) is ranked lower than
66% of the 281 Companies
in the Global Biotechnology industry.

( Industry Median: 1.67 vs. SHPGF: 1.00 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
SHPGF' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0.5  Med: 0.89 Max: 1.52
Current: 1
0.5
1.52
3-Year Average Share Buyback Ratio -2.20
SHPGF's 3-Year Average Share Buyback Ratio is ranked higher than
83% of the 547 Companies
in the Global Biotechnology industry.

( Industry Median: -11.20 vs. SHPGF: -2.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
SHPGF' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -50.3  Med: -2.1 Max: 0.4
Current: -2.2
-50.3
0.4

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.13
SHPGF's Price/Projected FCF is ranked higher than
80% of the 157 Companies
in the Global Biotechnology industry.

( Industry Median: 2.91 vs. SHPGF: 1.13 )
Ranked among companies with meaningful Price/Projected FCF only.
SHPGF' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.91  Med: 1.55 Max: 2.65
Current: 1.13
0.91
2.65
Price/Median PS Value 1.06
SHPGF's Price/Median PS Value is ranked lower than
57% of the 592 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. SHPGF: 1.06 )
Ranked among companies with meaningful Price/Median PS Value only.
SHPGF' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.52  Med: 0.96 Max: 2.68
Current: 1.06
0.52
2.68
Price/Peter Lynch Fair Value 3.97
SHPGF's Price/Peter Lynch Fair Value is ranked lower than
75% of the 67 Companies
in the Global Biotechnology industry.

( Industry Median: 1.63 vs. SHPGF: 3.97 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
SHPGF' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.54  Med: 1.27 Max: 4.25
Current: 3.97
0.54
4.25
Earnings Yield (Greenblatt) (%) 0.60
SHPGF's Earnings Yield (Greenblatt) (%) is ranked higher than
75% of the 923 Companies
in the Global Biotechnology industry.

( Industry Median: -8.20 vs. SHPGF: 0.60 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
SHPGF' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.6  Med: 5.5 Max: 8.4
Current: 0.6
0.6
8.4
Forward Rate of Return (Yacktman) (%) 21.08
SHPGF's Forward Rate of Return (Yacktman) (%) is ranked higher than
59% of the 118 Companies
in the Global Biotechnology industry.

( Industry Median: 15.03 vs. SHPGF: 21.08 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
SHPGF' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 1.5  Med: 2.4 Max: 28.9
Current: 21.08
1.5
28.9

More Statistics

Revenue (TTM) (Mil) $9,306
EPS (TTM) $ 0.52
Beta1.65
Short Percentage of Float0.00%
52-Week Range $49.09 - 68.67
Shares Outstanding (Mil)904.20

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 9,582 12,676 17,468 19,570
EPS ($) 4.47 5.36 6.48 8.15
EPS w/o NRI ($) 4.47 5.36 6.48 8.15
EPS Growth Rate
(3Y to 5Y Estimate)
12.71%
Dividends Per Share ($) 0.30 0.41 0.61
» More Articles for SHPGF

Headlines

Articles On GuruFocus.com
Third Avenue Value Fund Buys 2 Stocks and Adds to 2 Positions in Q4 Dec 23 2016 
Julian Robertson Sells Delta Air Lines, Alphabet Dec 07 2016 
John Paulson's Largest 3rd Quarter Trades Dec 01 2016 
Momenta Pharmaceuticals Announces Positive Results for Humira Biosimilar Nov 30 2016 
Samuel Isaly Makes 9 New Buys in 3rd Quarter Nov 04 2016 
Martin Whitman's Top Recent Investments Oct 12 2016 
John Paulson’s Health Care Picks Plunge in Flat Year for Sector Oct 06 2016 
Whitman's Third Avenue Buys 3 Pharma Stocks in 3rd Quarter Sep 27 2016 
Mairs and Power Buys Walt Disney, Exits Baxalta Sep 27 2016 
Third Avenue Value Fund 3rd Quarter Letter Sep 14 2016 

More From Other Websites
Lawsuit accuses Shire of monopolizing market for ADHD drug Jan 12 2017
PRESS DIGEST- Financial Times - Jan 12 Jan 11 2017
Mylan, other pharmaceutical firms see stocks decline after Trump comments Jan 11 2017
Pharmaceutical company agrees to ‘landmark’ settlement in Tampa federal court Jan 11 2017
Martin Whitman Invests in Homebuilder in 4th Quarter Jan 09 2017
For Shire PLC (ADR) (SHPG) Securing Hemophilia Market With Long Acting Version Is Crucial Jan 06 2017
Billionaire James Dinan Betting On These Stocks To Recover Losses Jan 05 2017
Shire Plc – Value Analysis (US OTC:SHPGF) : January 5, 2017 Jan 05 2017
Shire Plc breached its 50 day moving average in a Bullish Manner : SHPGF-US : January 4, 2017 Jan 04 2017
Kick-start 2017 with these explosive growth stocks Jan 03 2017
Pharma Stock Roundup: Cempra Plunges to 52-Week Low, Shire Drug Label Expanded Dec 30 2016
Shire Gets FDA Approval for Label Expansion of Adynovate Dec 28 2016
Shire Could Have A Game Changer In The Making Dec 22 2016
American Blood Gives a Boost to Asia’s Most Valuable Drugmaker Dec 15 2016
Shire PLC (ADR) (SHPG) Looks To Xenetic Biosciences Inc (XBIO) To Cement Hemophilia Market Share Dec 15 2016
Is Shinhan Financial Group Co., Ltd. (ADR) (SHG) Going To Burn Investors? Dec 15 2016
2 top healthcare shares for growth investors right now Dec 13 2016
Best Midcap Stocks To Buy According To Billionaire Loeb Dec 09 2016
3 Footsie value stocks for growth and income? Dec 06 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)